Discarded Bone Marrow for Hematology Research
Part of paid clinical trials in Memphis, Tennessee.
- Sponsor
- St. Jude Children's Research Hospital
- Study ID
- NCT04671212
- Status
- Recruiting
Conditions
- Hemoglobinopathies
Eligibility Criteria
- Sex
- ALL
- Age
- N/A - N/A
- Healthy Volunteers
- Not accepted
Study Details
The primary objective of this study is to establish a mechanism to obtain discarded bone marrow-containing bone samples from hemoglobinopathy, as well as non-hemoglobinopathy individuals. The processing of samples will help to understand how best to manipulate HSPC's from hemoglobinopathy patients with gene therapy and gene technologies in the laboratory environment. It will also allow us to establish a reservoir of samples that can be studied in the future to assess cellular function and fitness for transplant. Secondary objectives * To develop gene transfer and gene editing strategies as potentially curative therapy for hemoglobinopathies (e.g. sickle cell disease (SCD) and β-thalassemia). * To develop a drug treatment strategy which elevates the expression of fetal hemoglobin to a potentially curative level for hemoglobinopathies. * To examine the biology of bone marrow cells isolated from patients with hemoglobinopathies.
Key Dates
- Start date
- Jul 26, 2022
- Status verified
- Apr 2026
- Primary completion
- Jan 31, 2030
- Completion
- Jan 31, 2035
Study Design
- Enrollment
- 50 participants (estimated)
Arms
- Arm: Orthopedic Surgery PatientsParticipants receiving orthopedic surgery for clinical management that involve bone marrow containing bone discard.
Primary Outcome Measure
Collection, processing and storage of discarded bone marrow-containing bone samples from hemoglobinopathy, as well as non-hemoglobinopathy individuals. [ Time Frame: After completion of sample collection, approximately 10 years ]
Central Contacts
- Shannon McKinney-Freeman, Ph.D.888-226-4343
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| St. Jude Children's Research Hospital | Memphis | Tennessee | 38105 | Shannon McKinney-Freeman, Ph.D. (PRINCIPAL_INVESTIGATOR) |
Find similar trials in Memphis, TN
Related Studies
- A Long-term Follow-up Study in Participants Who Received CTX001PHASE3 · Enrolling By Invitation · Vertex Pharmaceuticals Incorporated · Palo Alto, California
- Evaluation of Efficacy and Safety of a Single Dose of CTX001 in Participants With Transfusion-Dependent β-Thalassemia and Severe Sickle Cell DiseasePHASE3 · Recruiting · Vertex Pharmaceuticals Incorporated · New York, New York
- A Long-Term Follow-Up Study of Participants With Sickle Cell Disease or Transfusion Dependent β-Thalassemia Who Received EDIT-301Enrolling By Invitation · Editas Medicine, Inc. · Oakland, California
- Campath/Fludarabine/Melphalan Transplant Conditioning for Non-Malignant DiseasesPHASE1/PHASE2 · Recruiting · Washington University School of Medicine · Phoenix, Arizona